Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Cost of Revenue came in at $32000.0 in Q1 2026, down 27.27% year-on-year from $44000.0 in Q1 2025, and down 37.25% on a QoQ basis from $51000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of Cost of Revenue data on file, last reported at $32000.0 in Q1 2026.
- On a quarterly basis, Cost of Revenue fell 27.27% year-over-year to $32000.0 in Q1 2026; TTM through Mar 2026 was $178000.0, a 16.82% decrease from a year earlier, with the FY2025 full-year figure at $190000.0, down 6.86% from the prior year.
- Cost of Revenue for Q1 2026 stood at $32000.0, down from $51000.0 in the prior quarter.
- Over the last five years, Cost of Revenue for OBIO reached as high as $68000.0 in Q3 2024 and fell as low as $32000.0 in Q1 2026.
- Historically, Cost of Revenue has averaged $48411.8 across 5 years, with a median of $47000.0 in 2023.
- Across the five-year window, Cost of Revenue soared 65.85% in 2024 and decreased 27.94% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $53000.0 in 2022, then fell by 11.32% to $47000.0 in 2023, then increased by 23.4% to $58000.0 in 2024, then fell by 12.07% to $51000.0 in 2025, then slumped by 37.25% to $32000.0 in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $32000.0 in Q1 2026, $51000.0 in Q4 2025, and $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 121.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | 32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,000.00 |
| Mar 31, 2026 | 32,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Dec 31, 2023 | 47,000.00 |